Manufacturer of Controlled Substances; Notice of Application; Johnson Matthey Pharmaceutical Materials, Inc., 19017 [2013-07140]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices
19017
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
DEPARTMENT OF LABOR
Drug Enforcement Administration
Drug Enforcement Administration
Office of the Secretary
Manufacturer of Controlled
Substances; Notice of Application;
Johnson Matthey Pharmaceutical
Materials, Inc.
Manufacturer of Controlled
Substances; Notice of Registration;
Siemens Healthcare Diagnostics, Inc.
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Annual
Funding Notice for Defined Benefit
Pension Plans
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 15,
2012, Johnson Matthey Pharmaceutical
Materials, Inc., Pharmaceutical Service,
25 Patton Road, Devens, Massachusetts
01434, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
By Notice dated November 27, 2012,
and published in the Federal Register
on December 5, 2012, 77 FR 72409,
Siemens Healthcare Diagnostics Inc.,
Attn: RA, 100 GBC Drive, Mail Stop 514,
Newark, Delaware 19702, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Drug
Schedule
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Nabilone (7379) ............................
Hydrocodone (9193) .....................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
II
II
II
II
II
II
II
I
II
II
mstockstill on DSK4VPTVN1PROD with NOTICES
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substances in
bulk and to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey. The controlled substances
manufactured in bulk at this facility will
be distributed to the company’s
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 28, 2013.
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator controls which are
DEA exempt products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siemens Healthcare Diagnostics Inc., to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Siemens Healthcare
Diagnostics Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–07140 Filed 3–27–13; 8:45 am]
[FR Doc. 2013–07141 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Mar<15>2010
20:20 Mar 27, 2013
Jkt 229001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
ACTION:
Notice.
SUMMARY: The Department of Labor
(DOL) has submitted the Employee
Benefits Security Administration
(EBSA) sponsored information
collection request (ICR) revision titled,
‘‘Annual Funding Notice for Defined
Benefit Pension Plans,’’ to the Office of
Management and Budget (OMB) for
review and approval utilizing
emergency review procedures, in
accordance with the Paperwork
Reduction Act of 1995, Public Law 104–
13, 44 U.S.C. chapter 35 (PRA) and 5
CFR 1320.13.
DATES: OMB approval of the revised ICR
has been requested by April 29, 2013.
Submit comments on or before April 26,
2013.
ADDRESSES: A copy of this ICR, with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained from the RegInfo.gov
Web site, https://www.reginfo.gov/
public/do/PRAMain, or by contacting G.
Christopher Cosby at, Department of
Labor-EBSA, Room N–5718, 200
Constitution Avenue NW., Washington,
DC 20210, telephone, (202) 693–8410;
FAX, (202) 219–4745 (these are not tollfree numbers); email,
cosby.chris@dol.gov.
Submit comments about this request
to the Office of Information and
Regulatory Affairs, Attn: OMB Desk
Officer for the Department of LaborEBSA, Office of Management and
Budget, Room 10235, 725 17th Street
NW., Washington, DC 20503, Fax: 202–
395–6881 (these are not toll-free
numbers), email:
OIRA_submission@omb.eop.gov; and G.
Christopher Cosby Department of LaborEBSA, Room N–5718, 200 Constitution
Avenue NW., Washington, DC 20210,
telephone, (202) 693–8410; FAX, (202)
219–4745 (these are not toll-free
numbers); email, cosby.chris@dol.gov.
SUPPLEMENTARY INFORMATION: On July 6,
2012, President Barrack Obama signed
the Moving Ahead for Progress in the
21st Century Act (MAP–21). The new
law provides funding interest-rate
stabilization for single employer defined
benefit (DB) plans, effective for plan
years beginning on and after January 1,
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Page 19017]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07140]
[[Page 19017]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Johnson Matthey Pharmaceutical Materials, Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 15, 2012, Johnson
Matthey Pharmaceutical Materials, Inc., Pharmaceutical Service, 25
Patton Road, Devens, Massachusetts 01434, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Nabilone (7379)............................ II
Hydrocodone (9193)......................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
------------------------------------------------------------------------
The company plans to utilize this facility to manufacture small
quantities of the listed controlled substances in bulk and to conduct
analytical testing in support of the company's primary manufacturing
facility in West Deptford, New Jersey. The controlled substances
manufactured in bulk at this facility will be distributed to the
company's customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 28, 2013.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-07140 Filed 3-27-13; 8:45 am]
BILLING CODE 4410-09-P
